Proinflammatory cytokines, nutritional support, and the cachexia syndrome: Interactions and therapeutic options

Cancer

Volumn 79, Issue 9, 1997, Pages 1828-1839

  Moldawer, Lyle L ^a   Copeland III, Edward M ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

anticytokine therapy; cytokine; inflammation; parenteral nutrition; protein calorie malnutrition

Indexed keywords

CILIARY NEUROTROPHIC FACTOR; CYTOKINE; CYTOKINE ANTIBODY; CYTOKINE RECEPTOR; INTERLEUKIN 1; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; MIFEPRISTONE; MUSCLE PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PHASE RESPONSE; ARTICLE; CACHEXIA; CANCER; CATABOLISM; CITRIC ACID CYCLE; CRITICAL ILLNESS; HUMAN; INFECTION; INFLAMMATION; NONHUMAN; NUTRIENT; NUTRITIONAL SUPPORT; PRIORITY JOURNAL; PROTEIN CALORIE MALNUTRITION; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROTEIN SYNTHESIS; RECEPTOR BINDING; RHEUMATOID ARTHRITIS; TOTAL PARENTERAL NUTRITION;

ANIMALS; CACHEXIA; CYTOKINES; HUMANS; INFLAMMATION; PARENTERAL NUTRITION, TOTAL;

EID: 0031004362     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970501)79:9<1828::AID-CNCR28>3.0.CO;2-Z     Document Type: Article

References (119)

1. Dudrick SJ, Wilmore DW, Vars HM, Rhoads JE. Long-term total parenteral nutrition with growth, development, and positive nitrogen balance. Surgery 1968; 64:134-42.
2. Copeland EM. Jonathan E. Rhoads lecture. Intravenous hyperalimentation and cancer. A historical perspective. JPEN J Parenter Enteral Nutr 1986; 10:337-42.
3. Copeland EM, Daly JM, Dudrick SJ. Nutrition and cancer. Int Adv Surg Oncol 1981; 4:1-13.
4. Copeland EM, Daly JM, Ota DM, Dudrick SJ. Nutrition, cancer, and intravenous hyperalimentation. Cancer 1979; 43:2108-116.
5. Issell BF, Valdivieso M, Zaren HA, et al. Protection against chemotherapy toxicity by IV hyperalimentation. Cancer Treat Rep 1978; 62:1139-1143.
6. Bistrian BR, Blackburn GL, Vitale J, Cochran D, Naylor J. Prevalence of malnutrition in general medical patients. JAMA 1976; 235:1567-70.
7. Bistrian BR, Blackburn GL, Hallowell E, Heddle R. Protein status of general surgical patients. JAMA 1974; 230:858-60.
8. Blackburn GL, Bistrian BR. Nutritional care of the injured and/ or septic patient. Surg Clin North Am 1976; 56:1195-1224.
9. Dudrick SJ, Copeland EM, Parenteral hyperalimentation. Surg Annu 1973; 5:69-95.
10. Clowes GH Jr., O'Donnell TF, Blackburn GL, Maki TN. Energy metabolism and proteolysis in traumatized and septic man. Surg Clin North Am 1976; 56:1169-84.
11. Dudrick SJ, Copeland EM, Daly JM, et al. A clinical review of nutritional support of the patient. JPEN J Parenter Enteral Nutr 1979; 3:444-51.
12. Copeland EM, Dudrick SJ. Intravenous hyperalimentation in inflammatory bowel disease, pancreatitis, and cancer. Surg Annu 1980; 12:83-101.
13. Kinney JM, Elwyn DH. Protein metabolism and injury. Annu Rev Nutr 1983; 3:433-66.
14. Elwyn DH. Nutritional requirements of adult surgical patients. Crit Care Med 1980; 8:9-20.
15. Bennegard K, Eden E, Ekman L, Schersten T, Lundholm K. Metabolic balance across the leg in weight-losing cancer patients compared to depleted patients without cancer. Cancer Res 1982; 42:4293-9.
16. Edstrom S, Bennegard K, Eden E, Lundholm K. Energy and tissue metabolism in patients with cancer during nutritional support. Arch Otolaryngol Head Neck Surg 1982; 108:697-9.
17. Burt ME, Aoki TT, Gorschboth CM, Brennan MF. Peripheral tissue metabolism in cancer-bearing man. Ann Surg 1983; 198:685-91.
18. Long CL, Blakemore WS. Energy and protein requirements in the hospitalized patient. JPEN J Parenter Enterai Nutr 1979; 3:69-71.
19. Harvey KB, Moldawer LL, Bistrian BR, Blackburn GL. Biological measures for the formulation of a hospital prognostic index. Am J Clin Nutr 1981; 34:2013-22.
20. Birkhahn RH, Long CL, Fitkin D, Jeevanandam M, Blakemore WS. Whole-body protein metabolism due to trauma in man as estimated by L-[15N]alanine. Am J Physiol 1981; 241:E64-71.
21. Birkhahn RH, Long CL, Fitkin D, Geiger JW, Blakemore WS. Effects of major skeletal trauma on whole body protein turnover in man measured by L-[1,14C]-leucine. Surgery 1980; 88:294-300.
22. Long CL, Jeevanandam M, Kim BM, Kinney JM. Whole body protein synthesis and catabolism in septic man. Am J Clin Nutr 1977; 30:1340-4.
23. Jeevanandam M, Legaspi A, Lowry SF, Horowitz GD, Brennan MF. Effect of total parenteral nutrition on whole body protein kinetics in cachectic patients with benign or malignant disease. JPEN J Parenter Enterai Nutr 1988; 12:229-36.
24. Pisters PW, Brennan MF. Amino acid metabolism in human cancer cachexia. Annu Rev Nutr 1990; 10:107-32.
25. Pomposelli JJ, Palombo JD, Hamawy KJ, Bistrian BR, Blackburn GL, Moldawer LL. Comparison of different techniques for estimating rates of protein synthesis in vivo in healthy and bacteraemic rats. Biochem J 1985; 226:37-42.
26. Kawamura I, Moldawer LL, Keenan RA, et al. Altered amino acid kinetics in rats with progressive tumor growth. Cancer Res 1982; 42:824-9.
27. Tayek JA, Istfan NW, Jones CT, Hamawy KJ, Bistrian BR, Blackburn GL. Influence of the Walker 256 carcinosarcoma on muscle, tumor, and whole-body protein synthesis and growth rate in the cancer-bearing rat. Cancer Res 1986; 46:5649-54.
28. Ternell M, Moldawer LL, Lonnroth C, Gelin J, Lundholm KG. Plasma protein synthesis in experimental cancer compared to paraneoplastic conditions, including monokine administration. Cancer Res 1987; 47:5825-30.
29. Andersson CE, Lonnroth IC, Gelin LJ, Moldawer LL, Lundholm KG. Pretranslational regulation of albumin synthesis in tumor-bearing mice. The role of anorexia and undernutrition. Gastroenterology 1991; 100:938-45.
30. Moyer ED, Border JR, McMenamy RH, Caruana J, Chenier R, Cerra FB. Multiple systems organ failure: V. Alterations in the plasma protein profile in septic trauma-effects of intravenous amino acids. J Trauma 1981; 21:645-9.
31. Wannemacher RWJ. Protein metabolism: applied biochemistry. In: Ghadimi H, editor. Total parenteral nutrition: premises and promises. New York: John Wiley and Sons, 1975; 85-153.
32. Kordula T, Rokita H, Koj A, Fiers W, Gauldie J, Baumann H. Effects of interleukin-6 and leukemia inhibitory factor on the acute phase response and DNA synthesis in cultured rat hepatocytes. Lymphokine Cytokine Res 1991; 10:23-6.
33. Gauldie J, Northemann W, Fey GH. IL-6 functions as an exocrine hormone in inflammation. Hepatocytes undergoing acute phase responses require exogenous IL-.J Immunol 1990; 144:3804-8.
34. Schooltink H, Stoyan T, Roeb E, Heinrich PC, Rose JS. Ciliary neurotrophic factor induces acute-phase protein expression in hepatocytes. FEBS Lett 1992; 314:280-4.
35. Nesbitt JE, Fuentes NL, Fuller GM. Ciliary neurotrophic factor regulates fibrinogen gene expression in hepatocytes by binding to the interleukin-6 receptor. Biochem Biophys Res Commun 1993; 190:544-50.
36. Fey GH, Hattori M, Northemann W, et al. Regulation of rat liver acute phase genes by interleukin-6 and production of hepatocyte stimulating factors by rat hepatoma cells. Ann N Y Acad Sci 1989; 557:317-29.
37. Baumann H, Strassmann G. Suramin inhibits the stimulation of acute phase plasma protein genes by IL-6-type cytokines in rat hepatoma cells. J Immunol 1993; 151:1456-62.
38. Ramadori G, Sipe JD, Dinarello CA, Mizel SB, Colten HR. Pretranslational modulation of acute phase hepatic protein synthesis by murine recombinant interleukin 1 (IL-1) and purified human IL-1. J Exp Med 1985; 162:930-42.
39. Perlmutter DH, Dinarello CA, Punsal PI, Golten HR. Cachectin/tumor necrosis factor regulates hepatic acute-phase gene expression. J Clin Invest 1986; 78:1349-54.
40. Moldawer LL, Andersson C, Gelin J, Lundholm KG. Regulation of food intake and hepatic protein synthesis by recombinant-derived cytokines. Am J Physiol 1988; 254:G450-6.
41. Dinarello CA, Cannon JG, Wolff SM, et al. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 1986; 163:1433-50.
42. Van Zee KJ, Stackpole SA, Montegut WJ, et al. A human tumor necrosis factor (TNF) α mutant that binds exclusively to the p55 TNF receptor produces toxicity in the baboon. J Exp Med 1994; 179:1185-91.
43. Fischer E, Marano MA, Barber AE, et al. Comparison between effects of interleukin-1 alpha administration and sublethal endotoxemia in primates. Am J Physiol 1991; 261:R442-52.
44. Thoenen H, Barde YA, Davies AM, Johnson JE. Neurotrophic factors and neuronal death. Ciba Found Svmp 1987; 126:82-95.
45. Davis S, Aldrich TH, Stahl N, et al. LIFR beta and gp130 as heterodimerizing signal transducers of the tripartite CNTF receptor. Science 1993; 260:1805-8.
46. Davis S, Yancopoulos GD. The molecular biology of the CNTF receptor. Curr Opin Cell Biol 1993; 5:281-5.
47. Espat NJ, Auffenberg T, Rosenberg JJ, et al. Ciliary neurotrophic factor is catabolic and shares with IL-6 the capacity to induce an acute phase response. Am J Physiol 1996; 271:R185-90.
48. Clark JT, Sahu A, Kalra PS, Balasubramaniam A, Kalra SP. Neuropeptide Y (NPY)-induced feeding behavior in female rats: comparison with human NPY ([Met17]NPY), NPY analog ([norLeu4]NPY) and peptide YY. Regul Pept 1987; 17:31-9.
49. Metcalf D, Gearing DP. Fatal syndrome in mice engrafted with cells producing high levels of the leukemia inhibitory factor. Proc Natl Acad Sci USA 1989; 86:5948-52.
50. Richards CD, Brown TJ, Shoyab M, Baumann H, Gauldie J. Recombinant oncostatin M stimulates the production of acute phase proteins in HepG2 cells and rat primary hepatocytes in vitro. J Immunol 1992; 148:1731-6.
51. Low SY, Taylor PM, Hundal HS, Pogson CI, Rennie MJ. Transport of L-glutamine and L-glutamate across sinusoidal membranes of rat liver. Effects of starvation, diabetes and corticosteroid treatment. Biochem J 1992; 284:333-40.
52. Fong Y, Moldawer LL, Shires GT, Lowry SF. The biologic characteristics of cytokines and their implication in surgical injury. Surg Gynecol Obstet 1990; 170:363-78.
53. Espat NJ, Cendan JC, Beierle EA, et al. PEG-BP-30 monotherapy attenuates the cytokine-mediated inflammatory cascade in baboon Escherichia coli septic shock. J Surg Res 1995; 59:153-8.
54. Zhu X-L, Ayala A, Zellweger R, Morrison MH, Chaudry IH. Peritoneal macrophages show increased cytokine gene expression following haemorrhagic shock. Immunology 1994; 83:378-83.
55. Marano MA, Moldawer LL, Fong Y, et al. Cachectin/TNF production in experimental burns and Pseudomonas infection. Arch Surg 1988; 123:1383-8.
56. He W, Fong Y, Marano MA, et al. Tolerance to endotoxin prevents mortality in infected thermal injury: association with attenuated cytokine responses. J Infect Dis 1992; 165:859-64.
57. Ballmer PE, McNurlan MA, Southorn BG, Grant I, Garlick PJ. Effects of human recombinant interleukin-1 beta on protein synthesis in rat tissues compared with a classical acute-phase reaction induced by turpentine. Rapid response of muscle to interleukin-1 beta. Biochem J 1991; 279:683-8.
58. Neufeld HA, Pace JG, Kaminski MV, et al. A probable endocrine basis for the depression of ketone bodies during infectious or inflammatory state in rats. Endocrinology 1980; 107:596-601.
59. Gershenwald JE, Fong YM, Fahey TJ, et al. Interleukin 1 receptor blockade attenuates the host inflammatory response. Proc Natl Acad Sci USA 1990; 87:4966-70.
60. Chizzonite R, Truitt T, Kilian PL, et al. Two high-affinity interleukin 1 receptors represent separate gene products. Proc Natl Acad Sci USA 1989; 86:8029.
61. Sims J, Gayle M, Slack J, et al. Interleukin 1 signaling occurs exclusively via the type I receptor. Proc Natl Acad Sci USA 1993; 90:6155-9.
62. Greenfeder SA, Nunes P, Kwee L, Labow M, Chizzonite RA, Ju G. Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex. J Biol Chem 1995; 270:13757-65.
63. Giri JG, Wells J, Dower SK, et al. Elevated levels of shed type II-IL-1 receptor in sepsis. Potential role for type II receptor regulation of IL-1 responses. J Immunol 1994; 153:5802-9.
64. Pruitt JH, Copeland EM, Moldawer LL. Interleukin-1, interleukin-1 receptor antagonist and interleukin-1 receptors in sepsis, shock and the systemic inflammatory response syndrome. Shock 1995; 3:235-51.
65. Tocco BR, Moldawer LL, Jones CT, Gerson B, Blackburn GL, Bistrian BR. The biological activity in vivo of recombinant murine interleukin 1 in the rat. Proc Soc Exp Biol Med 1986; 182:263-71.
66. Oldenburg HSA, Keller B, Lazarus D, et al. Interleukin-1 binding to its type I, but not type II receptor, modulates the in vivo acute phase response. Cytokine 1995; 7:510-6.
67. Solorzano CC, Kaibara A, Pruitt JH, et al. Mice lacking a functional IL-1 type I hut not a TNF type I receptor exhibit an attenuated acute phase response in acute inflammation. Surg Forum 1996; 47:72-3.
68. Fantuzzi G, Dinarello CA. The inflammatory response in interleukin-1 beta-deficient mice: comparison with other cytokine-related knock-out mice. J Leukoc Biol 1996; 59:489-93.
69. Sherry BA, Gelin J, Fong Y, et al. Anticachectin/tumor necrosis factor-alpha antibodies attenuate development of cachexia in tumor models. FASEB J 1989; 3:1956-62.
70. Oldenburg HS, Rogy MA, Lazarus DD, et al. Cachexia and the acute-phase protein response in inflammation are regulated by interleukin-6. Eur J Immunol 1993; 23:1889-94.
71. Kopf M, Baumann H, Freer G, et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994; 368:339-42.
72. Strassmann G, Fong M, Windsor S, Neta R. The role of interleukin-6 in lipopolysaccharide-induced weight loss, hypoglycemia and fibrinogen production, in vivo. Cytokine 1993; 5:285-90.
73. Strassmann G, Jacob CO, Evans R, Beall D, Fong M. Mechanisms of experimental cancer cachexia. Interaction between mononuclear phagocytes and colon-26 carcinoma and its relevance to IL-6-mediated cancer cachexia. J Immunol 1992; 148:3674-8.
74. Waring P, Wycherley K, Cary D, Nicola N, Metcalf D. Leukemia inhibitory factor levels are elevated in septic shock and various inflammatory body fluids. J Clin Invest 1992; 90:2031-7.
75. Alexander HR, Wong GG, Doherty GM, Venzon DJ, Fraker DL, Norton JA. Differentiation factor/leukemia inhibitory factor protection against lethal endotoxemia in mice: synergistic effect with interleukin 1 and tumor necrosis factor. J Exp Med 1992; 175:1139-42.
76. Hawes AS, Fischer E, Marano MA, et al. Comparison of peripheral blood leukocyte kinetics after live Escherichia coli, endotoxin, or interleukin-1 alpha administration. Studies using a novel interleukin-1 receptor antagonist. Ann Surg 1993; 218:79-90.
77. Moldawer LL, Marano MA, Wei H, et al. Cachectin/tumor necrosis factor-alpha alters red blood cell kinetics and induces anemia in vivo. FASEB J 1989; 3:1637-43.
78. Fischer E, Marano MA, Van Zee KJ, et al. Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest 1992; 89:1551-7.
79. Long CL, Schaffel N, Geiger JW, Schiller WR, Blakemore WS. Metabolic response to injury and illness: estimation of energy and protein needs from indirect calorimetry and nitrogen balance. JPEN J Parenter Enteral Nutr 1979; 3:452-6.
80. Kinney JM, Gump FE, Long CL. Energy and tissue fuel in human injury and sepsis. Adv Exp Med Biol 1972; 33:401-7.
81. Long CL. Energy balance and carbohydrate metabolism in infection and sepsis. Am J Clin Nutr 1977; 30:1301-10.
82. Wilmore DW. Hormonal responses and their effect on metabolism. Surg Clin North Am 1976; 56:999-1018.
83. Wilmore DW, Long JM, Mason AD Jr., Skreen RW, Pruitt BA. Catecholamines: mediator of the hypermetabolic response to thermal injury. Ann Surg 1974; 180:653-69.
84. O'Donnel TF, Clowes GH Jr., Blackburn GL, Ryan NT, Benotti PN, Miller JD. Proteolysis associated with a deficit of peripheral energy fuel substrates in septic man. Surgery 1976; 80:192-200.
85. Cerra FB, Siegel JH, Coleman B, Border JR, McMenamy RR. Septic autocannibalism. A failure of exogenous nutritional support. Ann Surg 1960; 192:570-80.
86. Clowes GH Jr., George BC, Villee CA Jr., Saravis CA. Muscle proteolysis induced by a circulating peptide in patients with sepsis or trauma. N Engl J Med 1983; 308:545-52.
87. Pekarek RS, Powanda MC, Wannemacher RWJ. The effect of leukocytic endogenous mediator (LEM) on serum copper and ceruloplasmin concentrations in the rat. Proc Soc Exp Biol Med 1972; 141:1029-31.
88. Pekarek RS, Wannemacher RW Jr., Beisel WR. The effect of leukocytic endogenous mediator (LEM) on the tissue distribution of zinc and iron. Proc Soc Exp Biol Med 1972; 140:685-8.
89. Wannemacher RW Jr., Pekarek RS, Klainer AS, et al. Detection of a leukocytic endogenous mediator-like mediator of serum amino acid and zinc depression during various infectious illnesses. Infect Immun 1975; 11:873-5.
90. Kampschmidt RF, Pulliam LA. Effect of human monocyte pyrogen on plasma iron, plasma zinc, and blood neutrophils in rabbits and rats. Proc Soc Exp Biol Med 1978; 158:32-5.
91. Merriman CR, Pulliam LA, Kampschmidt RF. Comparison of leukocytic pyrogen and leukocytic endogenous mediator. Proc Soc Exp Biol Med 1977; 154:224-7.
92. Kampschmidt RF, Upchurch HF. Effect of leukocytic endogenous mediator on plasma fibrinogen and haptoglobin. Proc Soc Exp Biol Med 1974; 146:904-7.
93. Klempner MS, Dinarello CA, Gallin JI. Human leukocytic pyrogen induces release of specific granule contents from human neutrophils. J Clin Invest 1978; 61:1330-6.
94. Dinarello CA, Renfer L, Wolff SM. Human leukocytic pyrogen: purification and development of a radioiminunoassay. Proc Natl Acad Sci USA 1977; 74:4624-7.
95. Hooper DC, Steer CJ, Dinarello CA, Peacock AC. Haptoglobin and albumin synthesis in isolated rat hepatocytes. Response to potential mediators of the acute-phase reaction. Biochim Biophys Acta 1981; 653:118-29.
96. Sobrado J, Moldawer LL, Bistrian BR, Dinarello CA, Blackburn GL. Effect of ibuprofen on fever and metabolic changes induced by continuous infusion of leukocytic pyrogen (interleukin 1) or endotoxin. Infect Immun 1983; 42:997-1005.
97. Yang RD, Moldawer LL, Sakamoto A, et al. Leukocyte endogenous mediator alters protein dynamics in rats. Metabolism 1983; 32:654-60.
98. Hasselgren PO, James JH, Benson DW, Li S, Fischer JE. Is there a circulating proteolysis-inducing factor during sepsis? Arch Surg 1990; 125:510-4.
99. Zamir O, Hasselgren PO, James H, Higashiguchi T, Fischer JE. Effect of tumor necrosis factor or interleukin-1 on muscle amino acid uptake and the role of glucocorticoids. Surg Gynecol Obstet 1993; 177:27-32.
100. Kettelhut IC, Goldberg AL. Tumor necrosis factor can induce fever in rats without activating protein breakdown in muscle or lipolysis in adipose tissue. J Clin Invest 1988; 81:1384-9.
101. Moldawer LL, Svaninger G, Gelin J, Lundholm KG. Interleukin 1 and tumor necrosis factor do not regulate protein balance in skeletal muscle. Am J Physiol 1987; 253:C766-73.
102. Fong Y, Moldawer LL, Marano M, et al. Cachectin/TNF or IL-1 alpha induces cachexia with redistribution of body proteins. Am J Physiol 1989; 256:R659-65.
103. Breuille D, Farge MC, Rose F, Arnal M, Attaix D, Obled C. Pentoxifylline decreases body weight loss and muscle protein wasting characteristics of sepsis. Am J Physiol 1993; 265:E660-6.
104. Voisin L, Gray K, Juransinski CV, et al. Altered expression of eukaryotic initiation factor 2B in skeletal muscle during sepsis. Am J Physiol 1996; 270:E43-50.
105. Juransinski CV, Kilpatrick L, Vary TC. Amrinone prevents muscle protein wasting during chronic sepsis. Am J Physiol 1997; 268:E636-41.
106. Zamir O, Hasselgren PO, Kunkel SL, Frederick J, Higashiguchi T, Fischer JE. Evidence that tumor necrosis factor participates in the regulation of muscle proteolysis during sepsis. Arch Surg 1992; 127:170-4.
107. Zamir O, Hasselgren PO, O'Brien W, Thompson RC, Fischer JE. Muscle protein breakdown during endotoxemia in rats and after treatment with interleukin-1 receptor antagonist (IL-1ra). Ann Surg 1992; 216:381-5.
108. Vary TC, Voisin TC, Cooney RN. Regulation of peptide-chain initiation during sepsis by interleukin-1 receptor antagonist. Am J Physiol 1997; 270:E513-20.
109. Lazarus DD, Moldawer LL, Lowry SF. Insulin-like growth factor-1 activity is inhibited by interleukin-1 alpha, tumor necrosis factor-alpha, and interleukin-. Lymphokine Cytokine Res 1993; 12:219-23.
110. Fan J, Char D, Bagby GJ, Gelato MC, Lang CH. Regulation of insulin-like growth factor-1 (IGF-I) and IGF-binding proteins by tumor necrosis factor. Am J Physiol 1995; 269:R1204-12.
111. Lang CH, Fan J, Cooney R, Vary TC. IL-1 receptor antagonist attenuates sepsis-induced alterations in the IGF system and protein synthesis. Am J Physiol 1996; 270:E430-7.
112. Hall AM, Angeras U, Zamir O, Hasseigren PO, Fischer JE. Interaction between corticosterone and tumor necrosis factor stimulated protein breakdown in rat skeletal muscle, similar to sepsis. Surgery 1990; 108:460-6.
113. Zamir O, Hasseigren PO, von Allmen D, Fischer JE. The effect of interleukin-1 alpha and the glucocorticoid receptor blocker RU 38486 on total and myofibrillar protein breakdown in skeletal muscle. J Surg Res 1991; 50:579-83.
114. Fisher CJ Jr., Slotman GJ, Opal SM, et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. The IL-1RA Sepsis-Syndrome Study Group [see comments]. Crit Care Med 1994; 22:12-21.
115. Fisher CJ Jr., Dhainaut J-FA, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial. JAMA 1994; 271: 1836-43.
116. Fisher CJ Jr., Opal SM, Dhainaut JF, et al. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group [see comments]. Crit Care Med 1993; 21:318-27.
117. Fisher CJ Jr., Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor:fc fusion protein. N Engl J Med 1996; 334:1697-1702.
118. Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial. JAMA 1995; 273:934-41.
119. Dezube BJ, Lederman MM, Spritzler JG, et al. High-dose pentoxifylline in patients with AIDS: inhibition of tumor necrosis factor production. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. J Infect Dis 1995; 171:1628-32.